Cross-Sector entity

Mounjaro (tirzepatide)

Product
6.5

Eli Lilly and Company is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. The 20-day window averages about 1.4 stories each week. The busiest single day carried 3. clinical-trial accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder.

4 verified stories tracked

Last mentioned: Aug 9, 2026

RSS updates
Share

Entity pulse

Recent coverage · Mounjaro (tirzepatide)

↑
4 stories
6.5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Mounjaro (tirzepatide)

Eli Lilly and Company is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. The 20-day window averages about 1.4 stories each week. The busiest single day carried 3. clinical-trial accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder. The tracked stories average 2.8 original sources each. This profile follows 4 Cross-Sector stories mentioning Mounjaro (tirzepatide) across the period from July 21, 2026 to August 9, 2026.

Stories tracked
4
Per week
1.4
Sources per story
2.8

Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Mounjaro (tirzepatide). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lawsuit Filed

    Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.

  2. FDA Approves Wegovy 7.2 mg

    Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.

Stories mentioning Mounjaro (tirzepatide) 4

Biotech pharma Neutral 5

Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr

The Indian pharmaceutical market expanded 12.1% by value in July 2026, but unit growth inched up only 1.6%, revealing a market shifting to high-value, specialty therapies. Anti-neoplastics and anti-diabetics led therapy-area growth, while Eli Lilly’s Mounjaro captured more than half of the diabetes segment with an 880% sales surge. For biotech and pharma firms, the data underscores the imperative to invest in innovation and patient access strategies.

2 sources

Source: aninews.in · bignewsnetwork.com